Introduction {#section1-1076029617736382}
============

Connective tissue diseases (CTDs), especially systemic lupus erythematosus (SLE),^[@bibr1-1076029617736382]^ are well known to be accompanied by a high-risk disease of developing various thrombotic events (THEs), including deep vein thrombosis (DVT), pulmonary embolism (PE), cerebral thrombosis, acute coronary syndrome, and thrombotic microangiopathy (TMA).^[@bibr2-1076029617736382]^ While the reported frequency of THEs is low in non-SLE CTD patients, including those with systemic sclerosis (SSc),^[@bibr3-1076029617736382]^ the risk of THEs in patients with SSc is still higher than in non-SSc individuals.^[@bibr4-1076029617736382][@bibr5-1076029617736382]--[@bibr6-1076029617736382]^ Indeed, cardiovascular disease accounts for 20% to 30% of all SSc deaths.^[@bibr7-1076029617736382]^ Various biomarkers of inflammation, thrombophilia, and organ dysfunction have been identified in patients with SSc.^[@bibr8-1076029617736382][@bibr9-1076029617736382][@bibr10-1076029617736382][@bibr11-1076029617736382]--[@bibr12-1076029617736382]^ It is also known that around half of patients with SSc having renal crisis develop TMA.^[@bibr13-1076029617736382]^

ADAMTS-13, a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13, cleaves unusual large multimers of von Willebrand factor (VWF) to inhibit the pathological activation of platelets. Thrombotic thrombocytopenic purpura, caused by a severe deficiency of ADAMTS-13,^[@bibr14-1076029617736382]^ is a major complication in CTD and causes around 20% of TMA in patients with CTD.^[@bibr15-1076029617736382]^ The serum levels of the vascular endothelial cell injury markers VWF, VWF propeptide (VWFpp),^[@bibr16-1076029617736382]^ and thrombomodulin (TM),^[@bibr17-1076029617736382]^ are elevated in patients with TMA or disseminated intravascular coagulation.

As we reported previously, the plasma levels of VWF and VWFpp are elevated in patients with SSc and antiphospholipid antibody syndrome (APS),^[@bibr18-1076029617736382]^ suggesting the presence of vascular endothelial cell injury. In the present study, we measured the plasma levels of ADAMTS-13, VWF, VWFpp, and several other hemostatic biomarkers in 233 patients with SSc and evaluated the relationship between these hemostatic biomarkers and several manifestations of SSc, including the spread of skin involvement, THE, interstitial lung disease (ILD), and complication of other CTDs.

Materials and Methods {#section2-1076029617736382}
=====================

The patients who consulted the clinics of dermatology or hematology at Mie University Hospital from January 1, 1994, to December 31, 2016, were enrolled in the present study. We diagnosed SSc according to the 2013 Classification Criteria for Systemic Sclerosis (American College of Rheumatology/European League Against Rheumatism \[ACR/EULAR\])^[@bibr19-1076029617736382]^ and classified patients as having limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc) based on the definition of LeRoy and Medsger.^[@bibr20-1076029617736382]^ Systemic lupus erythematosus was diagnosed by the 1997 update of the 1982 American College of Rheumatology Revised Criteria for Classification of Systemic Lupus Erythematosus.^[@bibr21-1076029617736382]^ Dermatomyositis and polymyositis were diagnosed based on the criteria of Bohan and Peter.^[@bibr22-1076029617736382],[@bibr23-1076029617736382]^ Sjögren syndrome was diagnosed based on the 2012 American College of Rheumatology Classification Criteria for Sjögren Syndrome.^[@bibr24-1076029617736382]^ Rheumatoid arthritis was diagnosed based on the 2010 Rheumatoid Arthritis Classification Criteria: ACR/EULAR.^[@bibr25-1076029617736382]^ As controls, healthy volunteers matched for age and sex were randomly selected.

Thrombosis was diagnosed based on the clinical manifestations and was confirmed by appropriate clinical and radiological examinations. The presence of PE and DVT was diagnosed by a whole-leg compression ultrasound examination and/or contrast computed tomography (CT). Cerebral and other organ thromboses were diagnosed by CT or magnetic resonance imaging. Thrombotic events diagnosed within 3 days after the onset were classified as acute THE. Thrombosis that developed more than a month before was classified as past THE. The presence of ILD was defined by the radiology reports: the presence of any ground-glass appearance, fibrotic interstitial changes, or honeycombing. ILD was then confirmed by high-resolution CT.^[@bibr26-1076029617736382],[@bibr27-1076029617736382]^

The plasma samples were prepared as reported previously.^[@bibr8-1076029617736382]^ In brief, plasma was separated using a 0.38% sodium citrate preparation with 3000*g* centrifugation at 4°C for 15 minutes. The plasma was stored at −80°C until use. The ADAMTS-13 activity was measured by Kokame method using a FRETS-VWF73 peptide (Peptide Institute, Inc, Osaka, Japan).^[@bibr28-1076029617736382]^ The plasma levels of VWF and VWFpp were measured by a VWF & Propeptide assay kit (GTI Diagnostics, Waukesha, Wisconsin).^[@bibr29-1076029617736382]^ The plasma levels of soluble fibrin (SF) and [d-]{.smallcaps}dimer were measured by 2 latex agglutination methods using IATRO-SF and LPIA-ACE [d]{.smallcaps}-Dimer II (LSI Medience Corporation, Tokyo, Japan), respectively. The plasma level of TM was measured by a chemiluminescent enzyme immunoassay using STACIA CLEIA TM (LSI Medience Corporation). The tricuspid regurgitation pressure gradient (TRPG) was measured using cardiac ultrasound.

The study protocol was approved by the human ethics review committee of Mie University School of Medicine (approval number: 2629), and informed consent was obtained from all the patients. This study was carried out in accordance with the principles of the Declaration of Helsinki.

Statistical Analyses {#section3-1076029617736382}
--------------------

The results were expressed as the median (25th-75th percentiles). Differences between groups were analyzed using the Mann-Whitney *U* test. *P* values of \<.05 were considered to indicate a statistically significant difference. The significance of a frequency was examined by the χ^2^ test. All statistical analyses were performed using the SPSS Statistics software program (version 22; IBM, New York, New York).

Results {#section4-1076029617736382}
=======

The laboratory data of 233 patients with SSc were serially investigated, including 173 patients with lcSSc (mean age, 64.5 \[11.7\] years) and 60 patients with dcSSc (mean age, 68.0 \[11.3\] years),^[@bibr19-1076029617736382]^ as shown in [Table 1](#table1-1076029617736382){ref-type="table"}. All of THEs that developed in lcSSc and dcSSc are shown in [Table 2](#table2-1076029617736382){ref-type="table"}. In patients with SSc, the plasma levels of ADAMTS-13 were significantly decreased and the plasma levels of VWF and VWFpp were significantly elevated compared to those of healthy controls (*P* \< .001; [Figure 1A--C](#fig1-1076029617736382){ref-type="fig"}).

###### 

Patients.

![](10.1177_1076029617736382-table1)

                                   n                                       n                                        n
  -------------------------------- ------- ------------------------------- ------------------------------- ----- -- ---
  All SSc: N = 233                 lcSSc   173                             lcSSc without other CTD or RA   113      
  lcSSc with other CTD or/and RA   60      RA                              16                                       
  SS                               12                                                                               
  SLE                              8                                                                                
  PM                               8                                                                                
  RA and SS                        5                                                                                
  SLE and RA                       4                                                                                
  DM                               3                                                                                
  SLE and SS                       3                                                                                
  SLE and PM                       1                                                                                
  dcSSc                            60      dcSSc without other CTD or RA   39                                       
  dcSSc with other CTD or/and RA   21      RA                              8                                        
  SLE                              4                                                                                
  SS                               3                                                                                
  PM                               2                                                                                
  DM                               1                                                                                
  SLE and RA                       1                                                                                
  SLE and SS                       1                                                                                
  RA and SS                        1                                                                                

Abbreviations: CTD, connective tissue disease; dcSSc, diffuse cutaneous SSc; DM, dermatomyositis; lcSSc, limited cutaneous SSc; PM, polymyositis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SS, Sjögren syndrome; SSc, systemic sclerosis.

###### 

All THEs Developed in LcSSc and DcSSc.

![](10.1177_1076029617736382-table2)

                            n                                            n
  ------------------------- ---------------- ----------- --------------- ---
  lcSSc (N = 173)           With acute THE   10 (5.8%)   DVT or/and PE   6
  Portal vein thrombosis    1                                            
  Splenic vein thrombosis   1                                            
  MI                        1                                            
  CI                        1                                            
  With past THE             19 (11%)         CI          12              
  DVT or/and PE             4                                            
  MI                        3                                            
  Without THE               144 (83.2%)                                  
  dcSSc (N = 60)            With acute THE   2 (3.3%)    TTP             2
  With past THE             6 (10%)          MI          3               
  CI                        3                                            
  Without THE               52 (86.7%)                                   

Abbreviations: CI, cerebral infarction; dcSSc, diffuse cutaneous SSc; DVT, deep vein thrombosis; lcSSc, limited cutaneous SSc; ; MI, myocardial infarction; PE, pulmonary thrombosis; THE, thrombotic event; TTP, thrombotic thrombocytopenic purpura.

![A, Plasma ADAMTS-13 activity in systemic sclerosis (SSc) and healthy volunteers. B, Plasma von Willebrand factor (VWF) levels in SSc and healthy volunteers. C, Plasma von Willebrand factor propeptide (VWFpp) levels in SSc and healthy volunteers. \*\*\**P* \< .001 (Mann-Whitney *U* test).](10.1177_1076029617736382-fig1){#fig1-1076029617736382}

Between patients with lcSSc and dcSSc, no significant difference was detected in values of ADAMTS-13, VWF, D-dimer, SF, TM/estimated glomerular filtration rate (eGFR), or TRPG. However, the plasma levels of VWFpp and eGFR were significantly higher in patients with dcSSc than in those with lcSSc (*P* \< .05). There were no significant differences in the risk of acute THE or past THE between lcSSc and dcSSc ([Table 3](#table3-1076029617736382){ref-type="table"}).

###### 

A Comparison Between LcSSc and DcSSc.^a^

![](10.1177_1076029617736382-table3)

                                 SSc: N = 233 (F/M, 211/22)   *P* Value                          
  ------------------------------ ---------------------------- ------------------------- -------- -----
  Age, years, mean (SD)          64.5 (11.7)                  68.0 (11.3)               .76      
  F/M                            158/15                       53/7                      .61      
  SSc                            SSc without other CTD        113                       39       .90
  SSc with other CTD             60                           21                                 
  THE in this study              Acute THE                    10                        2        .74
  Past THE                       19                           6                         1.0      
  Total                          29                           8                         .68      
  ILD                            25                           25                        \<.001   
  ADAMTS-13 (%)                  80.66 (60.76, 97.91)         87.29 (66.98, 98.87)      .10      
  VWF, U/dL                      140 (95, 162)                138 (114, 199)            .33      
  VWFpp, U/dL                    114 (85, 157)                128 (111, 159)            .049     
  [d]{.smallcaps}-dimer, μg/mL   0.52 (0.32, 1.39)            0.53 (0.35, 1.43)         .83      
  Soluble fibrin, μg/mL          1.00 (0.30, 3.00)            0.40 (0.30, 2.60)         .13      
  TM/eGFR, mL/minute/1.73 m^2^   0.1843 (0.1337, 0.2370)      0.1596 (0.1013, 0.2227)   .097     
  eGFR, mL/minute/1.73 m^2^      72.2 (60.3, 83.5)            81.2 (66.6, 90.2)         .016     
  TRPG, mm Hg                    20 (17, 26)                  21 (18, 23)               .26      

Abbreviations: CTD, connective tissue disease; dcSSc, diffuse cutaneous SSc; eGFR, estimated glomerular filtration rate; F, female; ILD, Interstitial lung disease; lcSSc, limited cutaneous SSc; M, male; SD, standard deviation; SSc, systemic sclerosis; THE, thrombotic event; TM, thrombomodulin; TRPG, tricuspid regurgitation pressure gradient; VWF, von Willebrand factor; VWFpp, von Willebrand factor propeptide.

^a^The data are presented as the median (Q1, Q3).

The plasma levels of [d]{.smallcaps}-dimer and SF in patients with SSc with THE were significantly higher than those in patients without THE (*P* \< .001 and *P* \< .01, respectively). The C-reactive protein (CRP), lactate dehydrogenase (LDH), prothrombin time (PT), and activated partial thromboplastin time (APTT) also showed significant difference between patients having SSc with and without THE ([Table 4](#table4-1076029617736382){ref-type="table"}).

###### 

A Comparison Between Patients Having SSc With and Without THE.^a^

![](10.1177_1076029617736382-table4)

                                    SSc: N = 233 (F/M, 211/22)   *P* Value                 
  --------------------------------- ---------------------------- ------------------------- --------
  lcSSc/dcSSc                       144/52                       21/16                     .49
  ILD                               40                           10                        .39
  Age, years                        65.0 (58.0, 73.0)            67.0 (60.5, 76.0)         .17
  ADAMTS-13, %                      85.49 (63.76, 99.15)         78.32 (37.50, 95.38)      .17
  VWF, U/dL                         136 (96, 165)                144 (128, 164)            .43
  VWFpp, U/dL                       118 (87, 156)                145 (98, 195)             .077
  [d]{.smallcaps}-dimer, μg/mL      0.50 (0.31, 1.07)            2.39 (0.73, 6.69)         \<.001
  Soluble fibrin, μg/mL             0.70 (0.30, 3.00)            3.75 (0.30, 21.80)        .0040
  TM/eGFR, ng/mL^2^/min/1.73 m^2^   0.1770 (0.1222, 0.2338)      0.1877 (0.1402, 0.2331)   .86
  eGFR, mL/min/1.73 m^2^            75.4 (63.7, 87.2)            68.5 (57.7, 78.5)         .072
  TRPG, mm Hg                       20 (17, 25)                  21 (20, 25)               .55
  PT, seconds                       11.5 (10.8, 12.1)            11.8 (11.1, 13.4)         .015
  APTT, seconds                     29.4 (27.0, 31.6)            30.1 (28.3, 35.6)         .039
  CRP, mg/dL                        0.080 (0.030, 0.38)          0.18 (0.040, 1.76)        .047
  LDH, IU/L                         201 (178, 235)               235(206, 320)             .0020
  IgG, mg/dL                        1256 (1095, 1555)            1291 (1008, 1651)         .95

Abbreviations: APTT, activated partial thromboplastin time; CRP, C-reactive protein; dcSSc, diffuse cutaneous SSc; eGFR, estimated glomerular filtration rate; F, female; IgG, immunoglobulin G; ILD, Interstitial lung disease; lcSSc, limited cutaneous SSc; LDH, Lactate dehydrogenase; M, male; PT, prothrombin time; SSc, systemic sclerosis; THE, thrombotic event; TM, thrombomodulin; TRPG, tricuspid regurgitation pressure gradient; VWF, von Willebrand factor; VWFpp, von Willebrand factor propeptide.

^a^The data are presented as the median (Q1, Q3).

The prevalence of ILD in patients with dcSSc was significantly higher than in those with lcSSc, in concordance with previous findings (*P* \< .001; [Table 3](#table3-1076029617736382){ref-type="table"}). Surprisingly, the plasma levels of VWF and VWFpp were significantly higher in the patients with SSc with ILD than in those without ILD (*P* \< .05). In patients with SSc having other CTDs, the plasma levels of VWF and VWFpp in patients with SSc with ILD were significantly high than in those without ILD (*P* \< .05; [Table 5](#table5-1076029617736382){ref-type="table"}).

###### 

A Comparison Between Patients Having SSc With and Without ILD.^a^

![](10.1177_1076029617736382-table5)

                                    Without ILD               With ILD                   *P* Value              
  --------------------------------- ------------------------- -------------------------- ---------------------- -----
  All SSc                           ADAMTS-13, %              83.11 (62.08, 99.65)       86.24 (61.25, 97.34)   .52
  VWF, U/dL                         132 (94, 162)             154 (132, 208)             .013                   
  VWFpp, U/dL                       114 (84, 157)             133 (109, 171)             .028                   
  D-dimer, μg/mL                    0.51 (0.31, 1.18)         1.20 (0.36, 2.63)          .052                   
  Soluble Fibrin, μg/mL             0.90 (0.30, 3.00)         0.50 (0.30, 3.00)          .63                    
  TM/eGFR, ng/mL^2^/min/1.73 m^2^   0.1817 (0.1192, 0.2327)   0.1600 (0.1412, 0.2801)    .98                    
  eGFR, mL/min/1.73 m^2^            75.6 (64.4, 88.2)         70.3 (61.1, 79.2)          .050                   
  TRPG, mm Hg                       21 (17, 25)               20 (17, 22)                .57                    
  SSc without other CTD             ADAMTS-13, %              85.41 (62.58, 102.92)      86.24 (46.34, 97.42)   1.0
  VWF, U/dL                         135 (90, 162)             151 (118, 163)             .23                    
  VWFpp, U/dL                       114 (83, 157)             117 (107, 147)             .56                    
  [d]{.smallcaps}-dimer, μg/mL      0.50 (0.29, 1.05)         0.76 (0.34, 1.97)          .14                    
  Soluble fibrin, μg/mL             0.90 (0.30, 3.00)         0.85 (0.30, 3.50)          .79                    
  TM/eGFR, ng/mL^2^/min/1.73 m^2^   0.1822 (0.1169, 0.2407)   0.1603 (0.1380, 0.2839)    .83                    
  eGFR (mL/min/1.73 m^2^            76.3 (65.0, 87.8)         71.1 (62.6, 79.6)          .15                    
  TRPG, mm Hg                       21 (17, 25)               19 (15, 26)                .47                    
  SSc with other CTD                ADAMTS-13, %              82.78 (55.23, 90.18)       84.78 (68.92, 97.28)   .28
  VWF, U/dL                         129 (93, 160)             166 (136, 190)             .015                   
  VWFpp, U/dL                       112 (84, 157)             152 (125, 192)             .018                   
  [d]{.smallcaps}-dimer, μg/mL      0.62 (0.43, 1.51)         1.23 (0.41 - 3.17)         .32                    
  Soluble fibrin, μg/mL             0.90 (0.30, 3.00)         0.50 (0.30, 5.08)          .72                    
  TM/eGFR, ng/mL^2^/min/1.73 m^2^   0.1808 (0.1266, 0.2192)   0.1490 (0.09376, 0.2638)   .91                    
  eGFR, mL/min/1.73 m^2^            74.8 (60.1, 89.0)         68.8 (57.5, 79.9)          .23                    
  TRPG, mm Hg                       20 (18, 22)               21 (19, 22)                .76                    

Abbreviations: CTD, connective tissue disease; eGFR, estimated glomerular filtration rate; ILD, Interstitial lung disease; SSc, systemic sclerosis; TM, thrombomodulin; TRPG, tricuspid regurgitation pressure gradient; VWF, von Willebrand factor; VWFpp, von Willebrand factor propeptide.

^a^The data are presented as the median (Q1, Q3).

The plasma [d]{.smallcaps}-dimer level of patients having SSc with other CTDs was significantly higher than that of patients having SSc without other CTDs (*P* \< .05; [Table 6](#table6-1076029617736382){ref-type="table"}). The plasma level of ADAMTS-13 was significantly lower in patients with SSc having a high [d]{.smallcaps}-dimer level (≥1 μg/mL) than in those with a low [d]{.smallcaps}-dimer level (\<1 μg/mL). Interestingly, patients with a high [d]{.smallcaps}-dimer level (≥1 μg/mL) showed higher VWF, VWFpp, SF, LDH, and CRP levels as well as daily and total corticosteroid doses and duration than patients with a low [d]{.smallcaps}-dimer level (\<1 μg/mL). In contrast, the TM/eGFR, eGFR, TRPG, age, PT, APTT, and immunoglobulin G titer showed no significant difference between the low and high [d]{.smallcaps}-dimer groups ([Table 7](#table7-1076029617736382){ref-type="table"}).

###### 

A Comparison Between Patients Having SSc With and Without Other CTD.^a^

![](10.1177_1076029617736382-table6)

                                     SSc Without Other CTD: n = 152   SSc With Other CTD: n = 81   *P* Value
  ---------------------------------- -------------------------------- ---------------------------- -----------
  ADAMTS-13, %                       85.57 (62.58, 101.23)            82.57 (59.27, 92.68)         .28
  VWF, U/dL                          136 (99, 162)                    140 (101, 194)               .21
  VWFpp, U/dL                        114 (87, 157)                    131 (100, 171)               .081
  [d]{.smallcaps}-dimer, μg/mL       0.50 (0.31, 1.16)                0.91 (0.41, 1.94)            .026
  Soluble fibrin, μg/mL              0.90 (0.30, 3.00)                0.70 (0.30, 3.00)            .92
  TM/eGFR, ng//mL^2^/min/1.73 m^2^   0.1813 (0.1202, 0.2425)          0.1757 (0.1272, 0.2215)      .79
  eGFR, mL/min/1.73 m^2^             75.7 (64.4, 86.5)                73.0 (60.3, 86.7)            .43
  TRPG, mm Hg                        21 (16, 26)                      20 (18, 22)                  .87

Abbreviations: CTD, connective tissue disease; eGFR, estimated glomerular filtration rate; SSc, systemic sclerosis; TM, thrombomodulin; TRPG, tricuspid regurgitation pressure gradient; VWF, von Willebrand factor; VWFpp, von Willebrand factor propeptide.

^a^The data are presented as the median (Q1, Q3).

###### 

A Comparison Between Patients Having SSc With Low and High D-Dimer Level.^a^

![](10.1177_1076029617736382-table7)

                                    [d]{.smallcaps}-Dimer \<1 μg/mL   [d]{.smallcaps}-Dimer ≥1 μg/mL   *P* Value
  --------------------------------- --------------------------------- -------------------------------- -----------
  lcSSc/dcSSc                       83/30                             54/17                            .73
  THE (acute or past)               8                                 24                               \<.001
  Acute THE                         0                                 10                               \<.001
  Past THE                          8                                 14                               .038
  ILD                               17                                21                               .024
  Age, years                        66.0 (57.0, 73.0)                 69.0 (60.0, 76.0)                .13
  ADAMTS-13, %                      87.58 (70.03, 102.09)             48.50 (37.50, 79.39)             .0010
  VWF, U/dL                         127 (85, 156)                     147 (132, 197)                   .012
  VWFpp, U/dL                       113 (85, 142)                     156 (126, 188)                   .0020
  Soluble fibrin, μg/mL             0.40 (0.30, 2.20)                 4.45 (1.43, 9.13)                \<.001
  TM/eGFR, ng/mL^2^/min/1.73 m^2^   0.1675 (0.1154, 0.2251)           0.1828 (0.1481, 0.2579)          .56
  eGFR, mL/min/1.73 m^2^            77.5 (63.7, 87.0)                 70.5 (63.2, 86.0)                .33
  TRPG, mm Hg                       21 (18, 25)                       21 (19, 28)                      .65
  PT, seconds                       11.6 (11.0, 12.3)                 11.6 (10.9, 12.4)                .80
  APTT, seconds                     29.7 (27.6, 32.3)                 29.8 (27.6, 33.3)                .82
  CRP, mg/dL                        0.060 (0.030, 0.17)               0.59 (0.12, 3.28)                \<.001
  LDH, IU/L                         197 (179, 230)                    220 (180, 291)                   .0090
  IgG, mg/dL                        1239 (1037, 1498)                 1323 (1029, 1693)                .65
  Dose of steroid                   0 (0, 5)                          5 (0, 10)                        .0010
  , prednisolone mg                                                                                    
  Duration of steroid, years        0.11 (0, 8.1)                     5.6 (0, 11.8)                    .0030
  Total dose of steroid             1288 (0, 16620)                   13500 (0, 28560)                 .0010
  , prednisolone mg                                                                                    

Abbreviations: APTT, activated partial thromboplastin time; CRP, C-reactive protein; dcSSc, diffuse cutaneous SSc; eGFR, estimated glomerular filtration rate; IgG, immunoglobulin G; ILD, Interstitial lung disease; lcSSc, limited cutaneous SSc; LDH, Lactate dehydrogenase; PT, prothrombin time; SSc, systemic sclerosis; THE, thrombotic event; TM, thrombomodulin; TRPG, tricuspid regurgitation pressure gradient; VWF, von Willebrand factor; VWFpp, von Willebrand factor propeptide.

^a^The data are presented as the median (Q1, Q3).

Discussion {#section5-1076029617736382}
==========

Systemic sclerosis induces systemic inflammation followed by severe vascular lesions of small arteries, smooth muscle involvement of digestive systems, and collagen deposition in skin, lung, and various internal organs. Clinically, typical skin lesions, including digital ulcers, nail fold capillary thrombosis, and digital pitting scars, are suggestive of the presence of ischemic vascular changes and hemostatic and/or coagulation abnormalities. In general, these changes are more apparent in dcSSc than in lcSSc.

However, in contrast to arterial vascular changes, the venous abnormalities associated with SSc have not been fully investigated. The incidence of venous thromboembolism (VTE) per 1000 person-years was reported to be 6.56 in patients with SSc, and the multivariable hazard ratio for VTE among patients with SSc was 3.47 in comparison to non-SSc patients.^[@bibr4-1076029617736382]^ Interestingly, the present study noted the development of acute THE in 5.8% of patients with lcSSc and 3.3% of patients with dcSSc and past THE in 11.0% of patients with lcSSc and 10.0% of patients with dcSSc. This suggests a high risk of THE in SSc. Surprisingly, the prevalence of THE showed no marked difference between patients with lcSSc and dcSSc. This implies the presence of other factors related to THE in patients with SSc. The overlap of other CTDs is common in patients with SSc, and CTDs other than SSc, especially SLE, induce the development of various THEs more often than does SSc.^[@bibr3-1076029617736382],[@bibr30-1076029617736382]^ The present study revealed an increase in the THE risk by the overlap of CTDs complicating hemostatic abnormalities.

Patients with SSc showed lower plasma levels of ADAMTS-13 and higher plasma levels of VWF and VWFpp than healthy participants, suggesting that high coagulability exists in patients with SSc. The plasma levels of [d]{.smallcaps}-dimer and SF were high in patients with THE, suggesting that SSc may be a causative condition for THE. Soluble fibrin has a shorter half-life than [d]{.smallcaps}-dimer, and [d]{.smallcaps}-dimer is a more sensitive marker for clinical diagnosis for THE.^[@bibr31-1076029617736382]^ Thus, the increased [d]{.smallcaps}-dimer levels in SSc suggest a thrombotic state.^[@bibr32-1076029617736382]^ A [d]{.smallcaps}-dimer level of ≥1 μg/mL has been proposed as a hallmark for a prethrombotic state.^[@bibr33-1076029617736382]^ In the present study, plasma levels of ADAMTS-13 were lower and plasma levels of VWF and VWFpp were higher in patients with SSc having high D-dimer levels (≥1 μg/mL) than in those with low [d]{.smallcaps}-dimer levels (\<1 μg/mL). These findings suggest that a decreased ADAMTS-13 level and elevated VWF and VWFpp levels indicate the presence of hypercoagulability in patients with SSc. Changes in the VWF and VWFpp levels might result from vascular endothelial cell injury.^[@bibr16-1076029617736382]^ The plasma levels of [d]{.smallcaps}-dimer in patients having SSc with other CTDs were higher than in patients having SSc without CTDs, possibly due to the presence of CTDs such as SLE or APS.^[@bibr8-1076029617736382]^

The plasma levels of VWFpp were significantly elevated in patients with dcSSc, suggesting the greater vascular endothelial cell injury in patients with dcSSc than in patients with lcSSc. The prevalence of ILD is known to be higher in patients with dcSSc than in patients with lcSSc. However, the pathogenesis of ILD has not been fully clarified. Surprisingly, the plasma levels of VWF and VWFpp were significantly higher in the patients with SSc with ILD than in those without ILD in the present study, suggesting a close relationship between ILD and vascular endothelial cell injury. Interestingly, very strong expression of VWF messenger RNA and the presence of immunoreactive VWF in the endothelial cells of murine small and microvessels of the lungs have been reported.^[@bibr34-1076029617736382]^ The present results suggest the involvement of VWF and VWFpp in pulmonary endothelial cells in the pathogenesis of ILD in patients with SSc.

In conclusion, SSc carries a high risk of THE, especially in patients with other CTDs. Plasma hemostasis-related markers are closely related to ILD and THE. These markers are important as markers of organ involvement as well as THE.
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